In a patient with rheumatic moderate-to-severe mitral regurgitation (MR) and tricuspid regurgitation (TR), is medical management alone appropriate?

Medical Management Alone is NOT Appropriate for Rheumatic Moderate-to-Severe MR and TR

In patients with rheumatic moderate-to-severe mitral and tricuspid regurgitation, medical management alone is insufficient—surgical intervention should be pursued, particularly when symptoms persist despite guideline-directed medical therapy (GDMT), as both valves typically require concomitant repair to prevent progressive right ventricular dysfunction, heart failure hospitalizations, and increased mortality. 1

Why Medical Management Fails in This Context

Rheumatic valve disease is a progressive structural pathology that does not respond to medical therapy alone. Unlike some forms of secondary MR where optimization of heart failure medications may reduce regurgitation, rheumatic disease causes:

• Irreversible leaflet thickening and fusion
• Annular dilatation that persists despite medical therapy
• Progressive right ventricular dysfunction from chronic volume overload

The natural history data demonstrates that in patients with ≥moderate TR managed medically, only 37% show regression at 1 year, while 10% progress to severe TR. Critically, severe TR carries a 1.73-1.92 times higher mortality risk, and approximately 70% of patients with severe TR at 1 year are those whose regurgitation did not improve with medical therapy alone 2.

The Surgical Imperative: Addressing Both Valves

Mitral Valve Management

For rheumatic MR, both ACC/AHA and ESC/EACTS guidelines provide Class I recommendations for surgery in symptomatic patients with severe primary MR, regardless of LV function 1. Even with moderate-to-severe (rather than strictly severe) MR in the rheumatic context, surgical correction is warranted when:

• Symptoms persist despite GDMT
• The patient is undergoing surgery for the tricuspid valve
• There is evidence of LV dysfunction (LVEF <60% or LVESD >40 mm)

Tricuspid Valve Management: The Critical Decision

The tricuspid valve should be repaired concomitantly when addressing rheumatic mitral disease with moderate-to-severe TR. The evidence strongly supports this approach:

Class I-B recommendation for TV surgery in patients with severe TR undergoing left-sided valve surgery 1

Class IIa-B recommendation for moderate TR when:

• Tricuspid annulus >40 mm (or >21 mm/m²)
• Prior signs of right-sided heart failure
• Atrial fibrillation is present 1, 3, 4

The rheumatic-specific data is particularly compelling: A propensity-matched study of 192 pairs showed that concomitant TV repair during rheumatic MV surgery resulted in:

• Lower postoperative low cardiac output syndrome (p=0.044)
• Significantly fewer TV reinterventions (1 vs 35 patients, p=0.004)
• Fewer rehospitalizations for heart failure (5 vs 40 patients, p<0.001)
• No increase in operative risk 5

Key Predictors That Mandate Intervention

Do not wait for severe symptoms. Intervene when you identify:

1. Tricuspid annular dilatation ≥21 mm/m² or ≥3.5 cm on echo—this is often irreversible even after mitral correction 3, 4
2. Right ventricular dilatation (OR 1.77 for TR progression) 2
3. Right atrial dilatation (OR 1.94 for TR progression) 2
4. Atrial fibrillation (OR 1.55 for TR progression)—a known driver of late TR development 2, 3
5. Pulmonary hypertension—though paradoxically, high pulmonary pressure may predict lower late TR rates, the presence of PH indicates advanced disease 3

Common Pitfalls to Avoid

Pitfall #1: Assuming TR will resolve after mitral surgery alone

• While mild TR may regress, moderate TR frequently persists or progresses
• Annular dilatation does not reverse with PH resolution—there is no "reverse remodeling" of the tricuspid annulus 3

Pitfall #2: Delaying intervention until TR becomes severe

• Isolated tricuspid surgery carries higher operative risk and worse outcomes
• Once RV dysfunction is established, outcomes deteriorate significantly 4

Pitfall #3: Relying on medical therapy in rheumatic disease

• Rheumatic pathology is structural and fibrotic—diuretics and afterload reduction do not address the underlying valve pathology
• 48.6% of patients whose TR regresses to mild will redevelop significant TR long-term 2

The Surgical Approach

Preferred technique: Rigid ring annuloplasty for both mitral and tricuspid valves

• Superior durability compared to non-ring techniques 3
• Valve repair is preferred over replacement unless there is advanced calcific disease 6, 4

Timing: Do not stage procedures—address both valves in a single operation

• Concomitant repair does not increase CPB time significantly (147.6 vs 168.2 minutes) 5
• Avoids the higher risk of isolated tricuspid reoperation

When Transcatheter Options May Be Considered

Transcatheter therapies (TEER for mitral, transcatheter tricuspid interventions) are Class IIa-IIb recommendations reserved for:

• High/prohibitive surgical risk patients
• Severe RV or LV dysfunction
• Severe pulmonary hypertension (contraindication for some transcatheter approaches)

However, robust rheumatic-specific data for transcatheter therapies is lacking 6, 4, and these should be considered only after Heart Team evaluation at a comprehensive valve center 7.

The Bottom Line Algorithm

1. Confirm severity with multimodality imaging (echo ± CMR/CT)
2. Measure tricuspid annulus—if ≥21 mm/m² or ≥3.5 cm, surgery is indicated regardless of TR grade
3. Assess RV function and pulmonary pressures—intervene before severe RV dysfunction develops
4. Optimize GDMT briefly (weeks, not months) while arranging surgical evaluation
5. Refer to Heart Valve Team at a comprehensive center for surgical planning
6. Perform concomitant mitral and tricuspid repair in a single operation

Medical management alone condemns these patients to progressive heart failure, repeated hospitalizations, and eventual inoperability. Surgical intervention is the definitive treatment.